BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 15943840)

  • 1. Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
    Wada T; Sasaki M; Kataoka H; Tanida S; Itoh K; Ogasawara N; Oshima T; Togawa S; Kubota E; Yamada T; Mori Y; Fujita F; Ohara H; Nakao H; Sobue S; Joh T; Itoh M
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():2-9. PubMed ID: 15943840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
    Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial.
    Bautista J; Fullerton H; Briseno M; Cui H; Fass R
    Aliment Pharmacol Ther; 2004 May; 19(10):1123-30. PubMed ID: 15142202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group.
    Wiklund I; Bardhan KD; Müller-Lissner S; Bigard MA; Bianchi Porro G; Ponce J; Hosie J; Scott M; Weir D; Fulton C; Gillon K; Peacock R
    Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):19-27. PubMed ID: 9615259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of treatment for gastro-oesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and Helicobacter pylori infection in Japan.
    Muramatsu A; Azuma T; Okajima T; Ohtani M; Dojo M; Yamazaki Y; Kuriyama M
    Aliment Pharmacol Ther; 2004 Jul; 20 Suppl 1():102-6. PubMed ID: 15298614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
    Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
    Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease.
    Pace F; Negrini C; Wiklund I; Rossi C; Savarino V;
    Aliment Pharmacol Ther; 2005 Aug; 22(4):349-56. PubMed ID: 16098002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Symptomatic therapy with famotidine in non-erosive gastro-esophageal reflux. Results of an open multicenter study].
    Heckers H; Lübbecke F
    Arzneimittelforschung; 1995 Apr; 45(4):499-504. PubMed ID: 7779150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
    Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
    Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial.
    Janiak P; Thumshirn M; Menne D; Fox M; Halim S; Fried M; Brühlmann P; Distler O; Schwizer W
    Aliment Pharmacol Ther; 2007 Nov; 26(9):1259-65. PubMed ID: 17944740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial: roxatidine vs omeprazole for non-erosive reflux disease.
    Nakamura K; Akiho H; Ochiai T; Motomura Y; Higuchi N; Okamoto R; Matsui N; Yasuda D; Akahoshi K; Kabemura T; Ihara E; Harada N; Ito T; Takayanagi R
    Hepatogastroenterology; 2010; 57(99-100):497-500. PubMed ID: 20698216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice.
    Venables TL; Newland RD; Patel AC; Hole J; Wilcock C; Turbitt ML
    Scand J Gastroenterol; 1997 Oct; 32(10):965-73. PubMed ID: 9361167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease.
    Størdal K; Johannesdottir GB; Bentsen BS; Knudsen PK; Carlsen KC; Closs O; Handeland M; Holm HK; Sandvik L
    Arch Dis Child; 2005 Sep; 90(9):956-60. PubMed ID: 16113133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group.
    Carlsson R; Dent J; Watts R; Riley S; Sheikh R; Hatlebakk J; Haug K; de Groot G; van Oudvorst A; Dalväg A; Junghard O; Wiklund I
    Eur J Gastroenterol Hepatol; 1998 Feb; 10(2):119-24. PubMed ID: 9581986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Bytzer P; van Zanten SV; Mattsson H; Wernersson B
    Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
    Castell D; Bagin R; Goldlust B; Major J; Hepburn B
    Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial.
    Dickman R; Emmons S; Cui H; Sewell J; Hernández D; Esquivel RF; Fass R
    Aliment Pharmacol Ther; 2005 Sep; 22(6):547-55. PubMed ID: 16167971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of omeprazole treatment in gastro-oesophageal reflux disease.
    Hendel J; Hendel L; Hage E; Hendel J; Aggestrup S; Nielsen OH
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):417-20. PubMed ID: 8804867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Famotidine in the management of gastro-oesophageal reflux.
    Okoth FA; Lule GN; Ogutu EO; Pilczer S; Dubois C
    East Afr Med J; 1994 Jan; 71(1):44-8. PubMed ID: 8055765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sleep dysfunction in patients with gastro-oesophageal reflux disease: prevalence and response to GERD therapy, a pilot study.
    Chand N; Johnson DA; Tabangin M; Ware JC
    Aliment Pharmacol Ther; 2004 Nov; 20(9):969-74. PubMed ID: 15521844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.